Ethnopharmacological validation of the antinociceptive potential of Calotropis gigantea L. flowers: Phytochemical characterization, safety evaluation, and mechanistic insights from in vivo models.
Calotropis gigantea shows promise for pain management based on its antinociceptive effects in rats, but further research is needed to confirm its efficacy in humans.
Where it sits
this study against the rest of the matrixyl corpusSummary and findings
The study evaluated the antinociceptive activity and safety profile of the ethanolic extract of Calotropis gigantea flowers in rats. The extract demonstrated significant dose-dependent antinociceptive effects and a favorable safety profile. Phytochemical analysis revealed high levels of phenolic and flavonoid constituents.
Abstract
<h4>Ethnopharmacological relevance</h4>Calotropis gigantea L. is traditionally used in South and Southeast Asia for the management of pain, inflammation, cough, burns, and other disorders. However, scientific evidence supporting its traditional use in pain management remains limited.<h4>Aim of the study</h4>The present study aimed to evaluate the antinociceptive activity, safety profile, phytochemical composition, and possible mechanisms underlying the antinociceptive effects of the ethanolic extract of flowers of C. gigantea (CGEE).<h4>Materials and methods</h4>Phytochemical profiling was performed using qualitative screening, total phenolic and flavonoid assays, DPPH radical scavenging assay, and HPLC analysis. Acute and subacute oral toxicity studies were conducted according to OECD guidelines 423 and 407, respectively. Antinociceptive activity was evaluated using hot plate, tail flick, formalin-induced paw licking, and acetic acid-induced writhing models in rats. Mechanistic investigations were carried out using Nalbin, Atropine, Glibenclamide, and Terazosin to assess the involvement of opioidergic, cholinergic, KATP channel, and noradrenergic pathways respectively.<h4>Results</h4>Phytochemical screening revealed the presence of phenolics, flavonoids, alkaloids, glycosides, tannins, saponins, amino acids, and reducing sugars. HPLC analysis identified chlorogenic acid, quercetin, gallic acid, syringic acid, vanillic acid, and coumaric acid derivatives. The extract exhibited considerable DPPH free radical scavenging activity with an IC<sub>50</sub> value of 145.77 ± 4.30 μg/mL. In addition, the extract contained high levels of phenolic and flavonoid constituents, with total phenolic content of 98.35 ± 3.12 mg gallic acid equivalents (GAE)/g extract and total flavonoid content of 65.20 ± 2.45 mg catechin equivalents (CE)/g extract. Acute and subacute toxicity studies showed no mortality or significant toxicological alterations. CGEE produced significant (p < 0.05) dose-dependent mg/kg. Mechanistic studies demonstrated the involvement of opioidergic, cholinergic, ATP-sensitive K<sup>+</sup> channel, and noradrenergic pathways.<h4>Conclusion</h4>The findings provide pharmacological evidence supporting the traditional use of C. gigantea in pain management. The antinociceptive effects may be associated with the synergistic action of phenolic and flavonoid constituents through modulation of multiple nociceptive pathways. CGEE also demonstrated a favorable safety profile, supporting its potential as a source of novel antinociceptive agents.
Background
Calotropis gigantea L. is traditionally used in South and Southeast Asia for pain management, but scientific validation of its efficacy is limited. Previous studies have suggested potential benefits, yet comprehensive evaluations of its antinociceptive properties are lacking. This study aims to provide pharmacological evidence for its traditional use by assessing its antinociceptive activity and safety profile.
Methods
The study involved phytochemical profiling, acute and subacute oral toxicity studies, and evaluation of antinociceptive activity in rats using hot plate, tail flick, formalin-induced paw licking, and acetic acid-induced writhing models. Mechanistic investigations were conducted using various pharmacological agents to assess the involvement of specific pathways.
Results
The extract exhibited an IC50 value of 145.77 ± 4.30 μg/mL for DPPH free radical scavenging activity. Total phenolic content was measured at 98.35 ± 3.12 mg GAE/g extract, and total flavonoid content was 65.20 ± 2.45 mg CE/g extract. Significant dose-dependent antinociceptive effects were observed (p < 0.05).
Interpretation
The findings align with previous literature suggesting the potential of C. gigantea for pain management. However, while the statistical significance is noted, the clinical relevance remains uncertain without human trials. Limitations include reliance on animal models and the absence of long-term safety data.
Key findings
- IC50 value of 145.77 ± 4.30 μg/mL for DPPH free radical scavenging activity.
- Total phenolic content of 98.35 ± 3.12 mg gallic acid equivalents (GAE)/g extract.
- Total flavonoid content of 65.20 ± 2.45 mg catechin equivalents (CE)/g extract.
- Significant (p < 0.05) dose-dependent antinociceptive effects observed.
Limitations
- Primarily animal study, results may not translate to humans.
- Short duration of toxicity studies.
- No long-term follow-up data reported.